BAF53B Inhibidores

BAF53 Inhibitors, as presented in the table above, are primarily compounds that indirectly influence the function of BAF53 by targeting chromatin modification processes or pathways related to chromatin remodeling. BAF53, being a part of the SWI/SNF complexes, is intricately involved in modulating chromatin structure, and thus, alterations in the chromatin landscape can impact its function. The majority of these inhibitors are histone deacetylase (HDAC) inhibitors like Panobinostat, Vorinostat, Trichostatin A, and MGCD0103. These compounds increase histone acetylation levels, leading to a more open chromatin state which can affect the activity of chromatin remodelers including BAF53. By altering the balance of acetylation on histones, these HDAC inhibitors can indirectly influence the function of BAF53 in gene regulation.

Bromodomain inhibitors such as JQ1 and I-BET762 target the recognition of acetylated lysines on histones, a crucial step in the regulation of gene expression. By inhibiting these interactions, they can indirectly impact the role of BAF53 in chromatin remodeling. Furthermore, compounds like GSK126, 5-Azacytidine, and Decitabine target mechanisms of histone methylation and DNA methylation, respectively. These alterations in epigenetic marks can influence the overall chromatin landscape, potentially impacting the functionality of BAF53 within the SWI/SNF complexes. Other compounds, such as Curcumin and Disulfiram, have broader effects on cellular signaling and epigenetic regulation. Their indirect influence on chromatin remodeling and, consequently, on BAF53 activity, highlights the complex interplay between various epigenetic modifiers and chromatin remodelers.